Table 3. Performance of the different models for assessing LVI in invasive breast cancer.
| Data set | Model | AUC (95% CI) | ACC | SEN | SPE | P value |
|---|---|---|---|---|---|---|
| Training set | TA | 0.812 (0.754–0.870) | 0.755 | 0.718 | 0.774 | 0.013 |
| PA | 0.830 (0.772–0.887) | 0.803 | 0.746 | 0.832 | 0.046 | |
| TPA | 0.878 (0.828–0.927) | 0.832 | 0.831 | 0.832 | 0.344 | |
| Clinical | 0.665 (0.591–0.739) | 0.591 | 0.775 | 0.496 | <0.001 | |
| Combined | 0.888 (0.841–0.934) | 0.822 | 0.845 | 0.810 | Ref. | |
| Validation set | TA | 0.752 (0.629–0.874) | 0.743 | 0.682 | 0.771 | 0.163 |
| PA | 0.757 (0.641–0.873) | 0.729 | 0.773 | 0.708 | 0.097 | |
| TPA | 0.825 (0.726–0.924) | 0.757 | 0.864 | 0.708 | 0.214 | |
| Clinical | 0.635 (0.497–0.774) | 0.671 | 0.500 | 0.750 | 0.001 | |
| Combined | 0.856 (0.769–0.943) | 0.757 | 0.909 | 0.688 | Ref. | |
| Test set | TA | 0.766 (0.664–0.867) | 0.659 | 0.897 | 0.542 | 0.192 |
| PA | 0.704 (0.583–0.824) | 0.693 | 0.759 | 0.661 | 0.051 | |
| TPA | 0.823 (0.726–0.921) | 0.795 | 0.862 | 0.763 | 0.203 | |
| Clinical | 0.686 (0.571–0.802) | 0.670 | 0.690 | 0.661 | 0.001 | |
| Combined | 0.853 (0.760–0.946) | 0.852 | 0.793 | 0.881 | Ref |
ACC, accuracy; AUC, area under the curve; CI, confidence interval; LVI, lymphovascular invasion; PA, peritumoral area; Ref., reference; SEN, sensitivity; SPE, specificity; TA, tumor area; TPA, tumor-plus-peritumoral area.